Form 4 for TXMD TherapeuticsMD, Inc.
Accepted 2023-01-25 00:00:00 ET · period of report 2023-01-23 · accession 0001209191-23-004871 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-01-25 | 2023-01-23 | TXMD | Donegan Michael C | Prin. Fin, Acctg. Off | M - OptEx | $0.00 | +4,365 | 6,519 | +203% | $0 |
| DM | 2023-01-25 | 2023-01-23+ | TXMD | Donegan Michael C | Prin. Fin, Acctg. Off | S - Sale+OE | $5.34 | -1,309 | 7,610 | -15% | -$6,990 |
| DM | 2023-01-25 | 2023-01-23 | TXMD | Donegan Michael C | Prin. Fin, Acctg. Off | M - OptEx | $0.00 | -4,365 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-23 | M | A | 2,400 | $0.00 | 8,919 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). |
| 2 | Common | Common Stock | 2023-01-23 | S | D | 1,302 | $5.34 | 7,617 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of ranging from $5.32 through $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. |
| 3 | Common | Common Stock | 2023-01-24 | S | D | 7 | $5.31 | 7,610 | D | — | — | |
| 4 | Common | Common Stock | 2023-01-23 | M | A | 1,066 | $0.00 | 6,000 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). |
| 5 | Common | Common Stock | 2023-01-23 | M | A | 380 | $0.00 | 4,934 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). |
| 6 | Common | Common Stock | 2023-01-23 | M | A | 519 | $0.00 | 6,519 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). |
| 7 | Derivative | Restricted Stock Units | 2023-01-23 | M | D | 380 | $0.00 | 0 | D | $0.00 · — to — | 380 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). (F4) The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". |
| 8 | Derivative | Restricted Stock Units | 2023-01-23 | M | D | 1,066 | $0.00 | 0 | D | $0.00 · — to — | 1,066 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). (F5) The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". |
| 9 | Derivative | Restricted Stock Units | 2023-01-23 | M | D | 2,400 | $0.00 | 0 | D | $0.00 · — to — | 2,400 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). (F7) The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". |
| 10 | Derivative | Restricted Stock Units | 2023-01-23 | M | D | 519 | $0.00 | 0 | D | $0.00 · — to — | 519 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). (F6) Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". |